BioClinica®, Inc., (NASDAQ: BIOC), a leading global provider of clinical trial management services, today announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM). Trident IWR’s unique interface provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a fraction of the time previously required.
“We believe that Trident will fundamentally change the IVR/IWR market. It provides the pharmaceutical industry with the technological innovation to drive the efficiencies their business requires. Trident gives customers the ability to build complex trials in a quicker and less costly manner than previous alternatives which require the development of custom programming for each new clinical trial,” said Mark Weinstein, CEO of BioClinica. “Sponsors who choose to standardize their IVR/IWR platform with BioClinica technologies will speed their research and development processes with greater control than ever before.”
Designed from inception as a web-based system, Trident simultaneously delivers world-class IVR phone support through the same simplified configuration process. It is fully synchronized with BioClinica Optimizer, the world’s leading clinical supply simulation and visualization package. Study designs simulated in Optimizer can configure Trident IWR to precisely match the optimal scenario identified using Optimizer. After deployment, Trident data can update Optimizer, and then Optimizer can re-simulate and reforecast, driving a process that will radically change the way clinical trials can be managed. BioClinica will conduct educational Trident-related webinars beginning in November 2010. For more information about these sessions please visit: http://www.bioclinica.com/webinars/.
Trident was designed by the team who created the world’s first parameter-driven IWR for a top five global pharmaceutical company. That software, designed by Tourtellotte Solutions, a company that BioClinica acquired in September 2009, is currently being used in more than 150 active clinical trials, and has been used in more than 300 trials since its inception.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.